Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000947871-21-000408
Filing Date
2021-04-08
Accepted
2021-04-07 18:00:54
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss216433_sc13d.htm SC 13D 138803
2 JOINT FILING AGREEMENT ss216433_sex9901.htm EX-99.1 7621
  Complete submission text file 0000947871-21-000408.txt   148082
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022
Business Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022 212-739-6451
Edgewise Therapeutics, Inc. (Subject) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92424 | Film No.: 21813241
SIC: 2834 Pharmaceutical Preparations